Lantheus Holdings, Inc. $LNTH Shares Bought by Harbor Capital Advisors Inc.

Key Points

• Harbor Capital Advisors Inc. raised its stake in Lantheus Holdings, Inc. by 24.7%, purchasing an additional 37,691 shares during the second quarter, now holding a total of 190,008 shares valued at about $15.6 million.
• Lantheus reported earnings of $1.57 per share for the last quarter, missing analysts' estimates, and experienced a 4.1% decrease in revenue year-over-year.
• Company insiders sold a total of 6,812,000 shares recently, valued at approximately $382.4 million, indicating significant insider trading activity.

Harbor Capital Advisors Inc. grew its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 24.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 190,008 shares of the medical equipment provider's stock after purchasing an additional 37,691 shares during the quarter. Lantheus makes up about 0.7% of Harbor Capital Advisors Inc.'s holdings, making the stock its 21st largest position. Harbor Capital Advisors Inc. owned 0.27% of Lantheus worth $15,554,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Lantheus by 3.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,084 shares of the medical equipment provider's stock valued at $1,162,000 after acquiring an additional 400 shares during the period. State of Alaska Department of Revenue lifted its position in shares of Lantheus by 2.7% during the 1st quarter. State of Alaska Department of Revenue now owns 8,142 shares of the medical equipment provider's stock valued at $794,000 after acquiring an additional 215 shares during the period. GAMMA Investing LLC lifted its position in shares of Lantheus by 12,517.1% during the 1st quarter. GAMMA Investing LLC now owns 128,442 shares of the medical equipment provider's stock valued at $12,536,000 after acquiring an additional 127,424 shares during the period. Swedbank AB increased its stake in shares of Lantheus by 11.0% during the 1st quarter. Swedbank AB now owns 1,228,743 shares of the medical equipment provider's stock worth $119,925,000 after purchasing an additional 121,500 shares in the last quarter. Finally, Strs Ohio purchased a new stake in shares of Lantheus during the 1st quarter valued at $4,529,000. Hedge funds and other institutional investors own 99.06% of the company's stock.

Analyst Upgrades and Downgrades

LNTH has been the topic of a number of recent analyst reports. JMP Securities cut their target price on shares of Lantheus from $112.00 to $73.00 and set a "market outperform" rating on the stock in a research note on Thursday, August 7th. William Blair restated a "market perform" rating on shares of Lantheus in a report on Wednesday, July 16th. TD Cowen dropped their price objective on shares of Lantheus from $95.00 to $80.00 and set a "buy" rating on the stock in a report on Monday, September 15th. B. Riley reduced their price target on shares of Lantheus from $109.00 to $84.00 and set a "buy" rating on the stock in a research report on Tuesday. Finally, Mizuho dropped their target price on shares of Lantheus from $120.00 to $70.00 and set an "outperform" rating for the company in a research note on Thursday, August 7th. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat, Lantheus presently has a consensus rating of "Moderate Buy" and an average price target of $85.50.

Lantheus Stock Down 2.2%

Lantheus stock traded down $1.15 on Friday, hitting $50.41. 2,275,969 shares of the stock traded hands, compared to its average volume of 1,112,992. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $118.21. The business's fifty day simple moving average is $60.91 and its 200 day simple moving average is $79.87. The firm has a market cap of $3.43 billion, a P/E ratio of 13.41 and a beta of 0.15. The company has a current ratio of 4.29, a quick ratio of 4.07 and a debt-to-equity ratio of 0.49.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 EPS for the quarter, missing analysts' consensus estimates of $1.65 by ($0.08). The business had revenue of $378.05 million during the quarter, compared to analysts' expectations of $389.69 million. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The firm's revenue for the quarter was down 4.1% on a year-over-year basis. During the same period in the prior year, the firm posted $1.80 earnings per share. As a group, sell-side analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insiders Place Their Bets

In other Lantheus news, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the firm's stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the transaction, the insider directly owned 3,477,227 shares of the company's stock, valued at $195,246,296.05. This trade represents a 49.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Rajiv A. Patel sold 3,365,000 shares of Lantheus stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the transaction, the insider owned 3,477,227 shares of the company's stock, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 6,812,000 shares of company stock worth $382,427,380 in the last 90 days. Company insiders own 1.50% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.